mProX™ Human PRKD2 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1222-KX451	Magic™ Human PKD2(PRKD2) in Vitro Assay	Human		Kinase Assay

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;KASUMI;U937

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research

Related Diseases

Angiolipoma; Conventional Lipoma

Gene ID

Human:25865

UniProt ID

Human:Q9BZL6

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

PRKD2, a member of the protein kinase D (PKD) family, has been implicated in various diseases, including polymorphous adenocarcinoma (PAC), osteoarthritis (OA), COVID-19 complications, prostate cancer (PCa), and cholangiocarcinoma (CCA). In PAC, PRKD2 gene fusions have been identified, along with novel fusion partners such as ARID1A and ARID1B. In OA, PRKD2 is associated with genetic regulatory effects and potential pathways involved in the disease. In COVID-19 ICU patients, increased levels of autoantibodies related to the male reproductive system, including PRKD2, have been observed. In PCa, PRKD2 is upregulated and may play an oncogenic role, suggesting the potential for PRKD inhibitors in treatment. In CCA, PRKD2, along with PRKD1 and PRKD3, has been identified as a critical regulator, and inhibition of the PKD family, including PRKD2, shows promise as a therapeutic approach. Overall, PRKD2 has diverse applications in different diseases, highlighting its significance as a potential target for diagnosis, treatment, and further research.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human PRKD2 Stable Cell Line (S01YF-1023-PY71). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Casey Smith (Verified Customer)

What is the role of PRKD2 in cervical cancer chemotherapy sensitivity? Feb 11 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

Knockdown of PRKD2 enhances chemotherapy sensitivity in cervical cancer via the TP53/CDKN1A pathway. Feb 11 2020

chat Jordan Garcia (Verified Customer)

How does PRKD2 influence T follicular helper cell differentiation? Jun 06 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

PRKD2 and Bcl6 form a mutually inhibitory feedback loop controlling the transition from naïve CD4+ T cells to T follicular helper cells. Jun 06 2023

Published Data

Fig.1 Proliferation of AML cells was facilitated by PRKD2.

The effect of PRKD2 overexpression on cell proliferation was first confirmed, and an increase in proliferation was observed in both KASUMI and U937 cell lines. The proliferation of AML cells was promoted by PRKD2 overexpression as demonstrated by the CCK8 assay.

Ref: Liu, Qian, et al. "PRKD2 promotes progression and chemoresistance of AML via regulating Notch1 pathway." OncoTargets and therapy (2019): 10931-10941.

Pubmed: 31849496

DOI: 10.2147/OTT.S233234

Research Highlights

Hahn, Elan. et al. "Comprehensive Molecular Characterization of Polymorphous Adenocarcinoma, Cribriform Subtype: Identifying Novel Fusions and Fusion Partners." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2023.
In the study conducted by the authors, it was found that Polymorphous Adenocarcinoma (PAC), a type of salivary gland cancer, is commonly associated with gene fusions in PRKD1, PRKD2, or PRKD3. This was mainly detected through fluorescence in situ hybridization (FISH) analysis, with a small portion being evaluated by next-generation sequencing (NGS). The authors aimed to further investigate these fusions through NGS, and identified 28 cases with gene fusions involving PRKD1, PRKD2, or PRKD3 in 51 successfully sequenced PACs. The most common gene partners were ARID1A and ARID1B, with a diverse group of 13 novel partners being identified. The findings suggest a need for a broader strategy of sequencing for molecular confirmation in challenging cases of PAC.
Hahn, Elan. et al. "Comprehensive Molecular Characterization of Polymorphous Adenocarcinoma, Cribriform Subtype: Identifying Novel Fusions and Fusion Partners." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2023.
Pubmed: 37595638 DOI: 10.1016/j.modpat.2023.100305

H Mullin, Benjamin. et al. "Leveraging osteoclast genetic regulatory data to identify genes with a role in osteoarthritis." Genetics, 2023.
In this study, a unique human osteoclast-like cell-specific expression quantitative trait locus (eQTL) resource was generated to investigate the genetics of bone disease. An integrative analysis was conducted, combining this dataset with recent osteoarthritis (OA) genome-wide association study (GWAS) results. Summary data-based Mendelian randomization (SMR) and colocalization analyses identified 38 genes potentially associated with OA, including some linked to Mendelian diseases featuring joint/skeletal abnormalities, such as BICRA, EIF6, CHST3, and FBN2. Several OA GWAS signals showed colocalization with multiple eQTL peaks, and pleiotropic effects on OA-risk and gene expression were observed at loci LINC01481, CPNE1, and EIF6, indicating the presence of an OA-risk gene cluster at 20q11.22.
H Mullin, Benjamin. et al. "Leveraging osteoclast genetic regulatory data to identify genes with a role in osteoarthritis." Genetics, 2023.
Pubmed: 37579195 DOI: 10.1093/genetics/iyad150